- Home
- PENN vs MLYS Comparison
PENN vs MLYS Comparison
Compare PENN & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PENN
- MLYS
- Stock Information
- Founded
- PENN 1972
- MLYS 2019
- Country
- PENN United States
- MLYS United States
- Employees
- PENN N/A
- MLYS N/A
- Industry
- PENN Hotels/Resorts
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- PENN Consumer Discretionary
- MLYS Health Care
- Exchange
- PENN Nasdaq
- MLYS Nasdaq
- Market Cap
- PENN 2.8B
- MLYS 2.9B
- IPO Year
- PENN 1994
- MLYS 2023
- Fundamental
- Price
- PENN $13.66
- MLYS $42.80
- Analyst Decision
- PENN Buy
- MLYS Strong Buy
- Analyst Count
- PENN 18
- MLYS 6
- Target Price
- PENN $21.94
- MLYS $46.40
- AVG Volume (30 Days)
- PENN 4.0M
- MLYS 1.8M
- Earning Date
- PENN 11-06-2025
- MLYS 11-10-2025
- Dividend Yield
- PENN N/A
- MLYS N/A
- EPS Growth
- PENN N/A
- MLYS N/A
- EPS
- PENN N/A
- MLYS N/A
- Revenue
- PENN $6,823,800,000.00
- MLYS N/A
- Revenue This Year
- PENN $8.36
- MLYS N/A
- Revenue Next Year
- PENN $5.50
- MLYS N/A
- P/E Ratio
- PENN N/A
- MLYS N/A
- Revenue Growth
- PENN 8.24
- MLYS N/A
- 52 Week Low
- PENN $13.24
- MLYS $8.24
- 52 Week High
- PENN $23.08
- MLYS $47.65
- Technical
- Relative Strength Index (RSI)
- PENN 30.96
- MLYS 53.06
- Support Level
- PENN $13.45
- MLYS $40.50
- Resistance Level
- PENN $14.56
- MLYS $45.00
- Average True Range (ATR)
- PENN 0.84
- MLYS 3.80
- MACD
- PENN -0.08
- MLYS -0.31
- Stochastic Oscillator
- PENN 10.17
- MLYS 63.98
About PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.